XML 62 R46.htm IDEA: XBRL DOCUMENT
v3.20.4

Property and Equipment (Brooklyn ImmunoTherapeutics, LLC) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2020 | Dec. 31, 2019
Property and Equipment |  |
5. | Fixed Assets, Net
Fixed assets are recorded at cost and consist of the following at December 31, 2019 and 2018:
|  | As of December 31, |
|  | 2019 |  |  | 2018 |
Site equipment |  | $ | 8,856,000 |  |  | $ | 11,566,000 |
Machinery and equipment |  |  | 1,570,000 |  |  |  | 1,887,000 |
Furniture and fixtures |  |  | 314,000 |  |  |  | 461,000 |
Leasehold improvements |  |  | 1,240,000 |  |  |  | 1,240,000 |
Vehicle |  |  | 15,000 |  |  |  | 15,000 |
|  |  | 11,995,000 |  |  |  | 15,169,000 |
Accumulated depreciation |  |  | (9,173,000 | ) |  |  | (10,502,000 | )
Total |  | $ | 2,822,000 |  |  | $ | 4,667,000 |
Depreciation expense totaled $2,358,000 and $2,382,000 for the years ended December 31, 2019 and 2018, respectively. The geographic breakdown of the Company’s long-term tangible assets for the last two fiscal years were as follows:
|  | As of December 31, |
|  | 2019 |  |  | 2018 |
United States |  | $ | 2,760,000 |  |  | $ | 4,526,000 |
Canada |  |  | 62,000 |  |  |  | 141,000 |
Total fixed assets |  | $ | 2,822,000 |  |  | $ | 4,667,000 |
Brooklyn Immunotherapeutics, LLC [Member] |  |
Property and Equipment |
NOTE 6 | PROPERTY AND EQUIPMENT
Property and equipment consist of the following:
|  | September 30, |  |  | December 31, |
|  | 2020 |  |  | 2019 |
Laboratory and manufacturing equipment |  | $ | 287,342 |  |  | $ | 261,164 |
Leasehold improvements |  |  | 414,504 |  |  |  | 414,504 |
|  |  | 701,846 |  |  |  | 675,668 |
Less: accumulated depreciation and amortization |  |  | (94,814 | ) |  |  | (21,905 | )
Property and equipment, net |  | $ | 607,032 |  |  | $ | 653,763 |
Depreciation expense charged to operations for the nine months ended September 30, 2020 was $72,909. Depreciation expense charged to operations for the nine months ended September 30, 2019 was $7,917. | NOTE 5 PROPERTY AND EQUIPMENT Property and equipment consist of the following:
|  | December 31, |
|  | 2019 |  |  | 2018 |
Laboratory and manufacturing equipment |  | $ | 261,164 |  |  | $ | 69,597 |
Leasehold improvements |  |  | 414,504 |  |  |  | - |
|  |  | 675,668 |  |  |  | 69,597 |
Less: accumulated depreciation and amortization |  |  | (21,905 | ) |  |  | (1,498 | )
Property and equipment, net |  | $ | 653,763 |  |  | $ | 68,099 |
Depreciation expense charged to operations during the year ended December 31, 2019 was $20,407. Depreciation expense charged to operations was $1,498 and $6,888 and during the periods from November 6, 2018 through December 31, 2018 and from January 1, 2018 through November 5, 2018, respectively. As of December 31, 2019, the Company has $64,461 of leasehold improvements that had not yet been placed into service. No depreciation expense is recorded on fixed assets in process until such time as the assets are completed and are placed into service. These fixed assets in process were placed into service on February 14, 2020.

X
- Definition The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -URI http://asc.fasb.org/topic&trid=2155823 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 360 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916 + Details
Name: | us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |